AstraZeneca to Invest $245 Million in Deal With Cellectis
By Ben Otto British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics...
United Kingdom Ben Otto Paris Based Cellectis Article Normal Biotechnology Services Healthcare Life Sciences
Source: marketwatch.com